Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Malchoff, A. Brufsky, G. Reardon, P. McDermott, E. Javier, C. Bergh, D. Rowe, C. Malchoff (1993)
A mutation of the glucocorticoid receptor in primary cortisol resistance.The Journal of clinical investigation, 91 5
E. Israel, J. Drazen, S. Liggett, H. Boushey, R. Cherniack, V. Chinchilli, D. Cooper, J. Fahy, J. Fish, J. Ford, M. Kraft, S. Kunselman, S. Lazarus, R. Lemanske, R. Martin, D. McLean, S. Peters, E. Silverman, C. Sorkness, S. Szefler, S. Weiss, C. Yandava (2000)
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.American journal of respiratory and critical care medicine, 162 1
D. McGraw, S. Forbes, Lisa Kramer, S. Liggett (1998)
Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.The Journal of clinical investigation, 102 11
S. Green, Jamal Turki, M. Innis, S. Liggett (1994)
Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.Biochemistry, 33 32
Daniel Lee, G. Currie, I. Hall, J. Lima, B. Lipworth (2003)
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.British journal of clinical pharmacology, 57 1
B. Lipworth, I. Hall, I. Aziz, K. Tan, A. Wheatley (1999)
β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapyClinical Science, 96
D. Hurley, D. Accili, C. Stratakis, M. Karl, N. Vamvakopoulos, E. Rorer, K. Constantine, Simeon Taylor, G. Chrousos (1991)
Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance.The Journal of clinical investigation, 87 2
A Fenech, IP Hall (2002)
Pharmacogenetics of asthmaBr J Clin Pharmacol, 53
E. Silverman, Jing Du, G. Sanctis, O. Rådmark, B. Samuelsson, J. Drazen, T. Collins (1998)
Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants.American journal of respiratory cell and molecular biology, 19 2
K. Tantisira, S. Lake, E. Silverman, L. Palmer, R. Lazarus, E. Silverman, S. Liggett, E. Gelfand, L. Rosenwasser, B. Richter, E. Israel, M. Wechsler, S. Gabriel, D. Altshuler, E. Lander, J. Drazen, S. Weiss (2004)
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.Human molecular genetics, 13 13
Soong Tan, I. Hall, J. Dewar, E. Dow, B. Lipworth (1997)
Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmaticsThe Lancet, 350
K Malmstrom, G Rodriguez-Gomez, J Guerra (1999)
Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/ Beclomethasone Study GroupAnn Intern Med, 130
Ian Sayers, S. Barton, S. Rorke, Bianca Beghé, Brooke Hayward, P. Eerdewegh, T. Keith, J. Clough, S. Ye, John Holloway, Anthony Sampson, S. Holgate (2003)
Inhaled corticosteroids and long acting β2 agonists can help patients with COPDThorax, 58
S. Green, D. Rathz, A. Schuster, S. Liggett (2001)
The Ile164 β2-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to GsEuropean Journal of Pharmacology, 421
I. Aziz, Ian Hall, L. McFarlane, B. Lipworth (1998)
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.The Journal of allergy and clinical immunology, 101 3
B. Lipworth, G. Koppelman, A. Wheatley, I. Jeune, W. Coutie, H. Meurs, H. Kauffman, D. Postma, I. Hall (2002)
β2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cellsThorax, 57
M Sanak, HU Simon, A Szczeklik (1997)
Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma (letter)Lancet, 350
A. Fenech, Ian Hall (2000)
Pharmacogenetics of asthma.The European respiratory journal, 15 3
K. Malmstrom, G. Rodriguez-Gomez, J. Guerra, C. Villarán, Andres Pieiro, Lynn Wei, B. Seidenberg, T. Reiss (1999)
Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic AsthmaAnnals of Internal Medicine, 130
N. Huizenga, J. Koper, P. Lange, H. Pols, R. Stolk, H. Burger, D. Grobbee, A. Brinkmann, F. Jong, S. Lamberts (1998)
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.The Journal of clinical endocrinology and metabolism, 83 1
Ramyani Gupta, A. Sheikh, D. Strachan, H. Anderson (2004)
Burden of allergic disease in the UK: secondary analyses of national databasesClinical & Experimental Allergy, 34
I Sayers, A Sampson (2002)
The Hereditary Basis of Allergic Diseases.
Joseph Donfack, P. Kogut, S. Forsythe, J. Solway, C. Ober (2003)
Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy.The Journal of allergy and clinical immunology, 111 3
P. Moore, J. Laporte, J. Abraham, I. Schwartzman, C. Yandava, E. Silverman, J. Drazen, M. Wand, R. Panettieri, S. Shore (2000)
Polymorphism of the β2-Adrenergic Receptor Gene and Desensitization in Human Airway Smooth MuscleAmerican Journal of Respiratory and Critical Care Medicine, 162
G. Currie, J. Lima, J. Sylvester, Daniel Lee, Wendy Cockburn, B. Lipworth (2003)
Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma.British journal of clinical pharmacology, 56 4
Ellen Reihsaus, M. Innis, N. Macintyre, S. Liggett (1993)
Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.American journal of respiratory cell and molecular biology, 8 3
R. Hancox, M. Sears, D. Taylor (1998)
Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma.The European respiratory journal, 11 3
K. Asano, T. Shiomi, N. Hasegawa, Hidetoshi Nakamura, H. Kudo, Tatsu Matsuzaki, H. Hakuno, K. Fukunaga, Yusuke Suzuki, M. Kanazawa, K. Yamaguchi (2002)
Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma.Pharmacogenetics, 12 7
A. Fenech, M. Ebejer, A. Felice, R. Ellul-Micallef, I. Hall (2001)
Mutation screening of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjectsBritish Journal of Pharmacology, 133
I. Sayers, A. Sampson (2002)
Genetic regulation of leukotriene production and activity
K. Jones, B. Porjesz, L. Almasy, L. Bierut, A. Goate, Jen Wang, D. Dick, A. Hinrichs, J. Kwon, J. Rice, J. Rohrbaugh, Heather Stock, William Wu, L. Bauer, D. Chorlian, R. Crowe, H. Edenberg, T. Foroud, V. Hesselbrock, S. Kuperman, J. Nurnberger, S. O'Connor, M. Schuckit, Arthur Stimus, J. Tischfield, T. Reich, H. Begleiter (2004)
Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: implications for human brain dynamics and cognition.International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 53 2
J. Lima, D. Thomason, Mohamad Mohamed, L. Eberle, T. Self, Julie Johnson (1999)
Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamicsClinical Pharmacology & Therapeutics, 65
I. Sayers, S. Barton, S. Rorke, J. Sawyer, Q. Peng, B. Beghé, S. Ye, T. Keith, J. Clough, J. Holloway, A. Sampson, S. Holgate (2003)
Promoter polymorphism in the 5‐lipoxygenase (ALOX5) and 5‐lipoxygenase‐activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian populationClinical & Experimental Allergy, 33
Satoru Koyano, Yoshiro Saito, M. Nagano, K. Maekawa, Y. Kikuchi, N. Murayama, T. Fujino, S. Ozawa, T. Nakajima, Kenji Matsumoto, H. Saito, J. Sawada (2003)
Functional Analysis of Three Genetic Polymorphisms in the Glucocorticoid Receptor GeneJournal of Pharmacology and Experimental Therapeutics, 307
K. Small, Kari Brown, C. Theiss, Carrie Seman, S. Weiss, S. Liggett (2003)
An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation.Pharmacogenetics, 13 9
Anthony Sampson, A. Cowburn, K. Sładek, L. Adamek, E. Niżankowska, Andrzej Szczeklik, B. Lam, J. Penrose, K. Austen, S. Holgate (1997)
Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients.International archives of allergy and immunology, 113 1-3
A. Stevens, D. Ray, E. Zeggini, S. John, H. Richards, C. Griffiths, R. Donn (2004)
Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype.The Journal of clinical endocrinology and metabolism, 89 2
Robin Taylor, Je Drazen, G. Herbison, C. Yandava, R. Hancox, Ian Town, D. Taylor (2000)
Asthma exacerbations during long term (cid:226) agonist use: influence of (cid:226) 2 adrenoceptor polymorphism
M. Sanak, H. Simon, A. Szczeklik (1997)
Leukotriene C 4 synthase promoter polymorphism and risk of aspirin-induced asthmaThe Lancet, 350
A. Parola, B. Kobilka (1994)
The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis.The Journal of biological chemistry, 269 6
DR Taylor, JM Drazen, GP Herbison (2000)
Asthma exacerbations during long-term beta agonist use: influence of beta(2) adrenoceptor polymorphismThorax, 55
S. Green, G. Cole, M. Jacinto, M. Innis, S. Liggett (1993)
A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor.The Journal of biological chemistry, 268 31
S. Johnatty, M. Abdellatif, L. Shimmin, R. Clark, E. Boerwinkle (2002)
β2 adrenergic receptor 5′ haplotypes influence promoter activityBritish Journal of Pharmacology, 137
F. Martinez, P. Graves, M. Baldini, S. Solomon, R. Erickson (1997)
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.The Journal of clinical investigation, 100 12
J. Drazen, C. Yandava, L. Dubé, Natalie Szczerback, Richard Hippensteel, A. Pillari, E. Israel, N. Schork, E. Silverman, D. Katz, J. Drajesk (1999)
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatmentNature Genetics, 22
A. Sampson, Salman Siddiqui, D. Buchanan, P. Howarth, S. Holgate, J. Holloway, I. Sayers (2000)
Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukastThorax, 55
S. Fowler, I. Hall, A. Wilson, A. Wheatley, B. Lipworth (2002)
5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonistsEuropean Journal of Clinical Pharmacology, 58
E. Lander, L. Linton, B. Birren, C. Nusbaum, M. Zody, J. Baldwin, K. Devon, K. Dewar, M. Doyle, W. Fitzhugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. Howland, L. Kann, J. Lehoczky, R. Levine, P. McEwan, K. McKernan, J. Meldrim, J. Mesirov, C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, Y. Stange-Thomann, N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne, J. Mullikin, A. Mungall, R. Plumb, M. Ross, R. Shownkeen, S. Sims, R. Waterston, R. Wilson, L. Hillier, J. McPherson, M. Marra, E. Mardis, L. Fulton, A. Chinwalla, K. Pepin, W. Gish, S. Chissoe, M. Wendl, K. Delehaunty, T. Miner, A. Delehaunty, J. Kramer, L. Cook, R. Fulton, D. Johnson, P. Minx, S. Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T. Slezak, N. Doggett, J. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, R. Gibbs, D. Muzny, S. Scherer, J. Bouck, E. Sodergren, K. Worley, C. Rives, J. Gorrell, M. Metzker, S. Naylor, R. Kucherlapati, D. Nelson, G. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J. Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, É. Pelletier, C. Robert, P. Wincker, D. Smith, L. Doucette-Stamm, M. Rubenfield, K. Weinstock, H. Lee, J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. Taudien, A. Rump, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood, L. Rowen, A. Madan, S. Qin, R. Davis, N. Federspiel, A. Abola, M. Proctor, R. Myers, J. Schmutz, M. Dickson, J. Grimwood, D. Cox, M. Olson, R. Kaul, N. Shimizu, K. Kawasaki, S. Minoshima, G. Evans, M. Athanasiou, R. Schultz, B. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach, R. Reinhardt, W. McCombie, M. Bastide, N. Dedhia, H. Blöcker, K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J. Bailey, A. Bateman, S. Batzoglou, E. Birney, P. Bork, D. Brown, C. Burge, L. Cerutti, H. Chen, D. Church, M. Clamp, R. Copley, T. Doerks, S. Eddy, E. Eichler, T. Furey, J. Galagan, J. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K. Hokamp, W. Jang, L. Johnson, T. Jones, S. Kasif, A. Kaspryzk, S. Kennedy, W. Kent, P. Kitts, E. Koonin, I. Korf, D. Kulp, D. Lancet, Gwênlyn Glusman, T. Lowe, A. McLysaght, T. Mikkelsen, J. Moran, N. Mulder, V. Pollara, C. Ponting, G. Schuler, J. Schultz, G. Slater, A. Smit, E. Stupka, J. Szustakowki, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y. Wolf, K. Wolfe, S. Yang, R. Yeh, F. Collins, M. Guyer, J. Peterson, A. Felsenfeld, K. Wetterstrand, A. Patrinos, M. Morgan, P. Jong, J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, Y. Chen, Vacslav Glukhov (2001)
Initial sequencing and analysis of the human genome.Nature, 409 6822
Jeong-Hee Choi, Hae‐Sim Park, H. Oh, J. Lee, Y. Suh, Choon-Sik Park, H. Shin (2004)
Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenaseHuman Genetics, 114
I Sayers, S Barton, S Rorke (2003)
Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthmaThorax, 58
Connie Drysdale, D. McGraw, Catharine Stack, J. Stephens, R. Judson, K. Nandabalan, Kevin Arnold, G. Ruaño, S. Liggett (2000)
Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.Proceedings of the National Academy of Sciences of the United States of America, 97 19
K. In, K. Asano, D. Beier, J. Grobholz, P. Finn, E. Silverman, E. Silverman, T. Collins, Andrew Fischer, T. Keith, K. Serino, S. Kim, G. Sanctis, C. Yandava, A. Pillari, P. Rubin, J. Kemp, E. Israel, W. Busse, D. Ledford, J. Murray, A. Segal, D. Tinkleman, J. Drazen (1997)
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.The Journal of clinical investigation, 99 5
L. Mastalerz, E. Niżankowska, M. Sanak, F. Mejza, M. Pierzchalska, S. Bazan-Socha, A. Bestyńska-Krypel, A. Ćmiel, A. Szczeklik (2002)
Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonistEuropean Journal of Clinical Investigation, 32
A. Fenech, C. Billington, C. Swan, S. Richards, T. Hunter, M. Ebejer, A. Felice, R. Ellul-Micallef, I. Hall (2004)
Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle.American journal of respiratory cell and molecular biology, 30 5
D Taylor, Martin Kennedy (2002)
Beta-adrenergic receptor polymorphisms and drug responses in asthma.Pharmacogenomics, 3 2
A patient’s response to asthma therapy is determined by both genetic and environmental factors. In the past 10 years, we have witnessed significant progress in the field of asthma pharmacogenetics—the study of how a patient’s genetic background determines the efficacy and potential for adverse effects to current asthma medication. There are now clear examples of gene polymorphisms that can influence responses to β2-agonists, glucocorticosteroids, and leukotriene modifier drugs, the three main classes of medication used clinically to treat asthma. Identification of genetic polymorphism that predicts drug responses has the potential to lead to the development of new therapeutics, improve asthma management, and reduce serious episodes and hospitalizations. In this review, we discuss the current understanding of asthma pharmacogenetics, focusing on the main three classes of drugs currently used clinically.
Current Allergy and Asthma Reports – Springer Journals
Published: May 28, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.